Winrevair (sotatercept-csrk) significantly reduced the risk of death, lung transplant, or hospitalization in people with PAH.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback